Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
Elevation Oncology (Nasdaq: ELEV) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Joseph J. Ferra, President and Chief Executive Officer, will engage in a fireside chat on Tuesday, December 3, 2024, at 8:30 a.m. ET. The company, which specializes in developing selective cancer therapies for patients with solid tumors, will provide a live webcast of the event, accessible through their Investor Relations website. A replay will also be available for those unable to attend the live presentation.
Elevation Oncology (Nasdaq: ELEV) ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler. Joseph J. Ferra, Presidente e Direttore Esecutivo, parteciperà a una chiacchierata informale martedì 3 dicembre 2024, alle 8:30 ET. La società, che si specializza nello sviluppo di terapie selettive per il cancro per pazienti con tumori solidi, offrirà una diretta dell'evento, accessibile attraverso il loro sito web delle Relazioni con gli Investitori. Una registrazione sarà disponibile anche per chi non potrà partecipare alla presentazione dal vivo.
Elevation Oncology (Nasdaq: ELEV) ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. Joseph J. Ferra, Presidente y Director Ejecutivo, participará en una charla informal el martes 3 de diciembre de 2024, a las 8:30 a.m. ET. La compañía, que se especializa en el desarrollo de terapias selectivas contra el cáncer para pacientes con tumores sólidos, ofrecerá una transmisión en vivo del evento, accesible a través de su sitio web de Relaciones con los Inversores. También estará disponible una repetición para aquellos que no puedan asistir a la presentación en vivo.
Elevation Oncology (Nasdaq: ELEV)는 Piper Sandler 제36회 연례 건강 회의에 참석한다고 발표했습니다. Joseph J. Ferra CEO는 2024년 12월 3일 화요일 오전 8시 30분 ET에 화기애애한 대화에 참여할 예정입니다. 고형 종양 환자를 위한 선택적 암 요법 개발을 전문으로 하는 회사는 이벤트의 생중계를 제공하며, 투자자 관계 웹사이트를 통해 접근할 수 있습니다. 생중계에 참석할 수 없는 분들을 위해 재방송도 제공될 예정입니다.
Elevation Oncology (Nasdaq: ELEV) a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. Joseph J. Ferra, Président et Directeur Général, participera à une discussion informelle le mardi 3 décembre 2024, à 8h30 HE. L'entreprise, spécialisée dans le développement de thérapies ciblées contre le cancer pour les patients atteints de tumeurs solides, proposera une diffusion en direct de l'événement, accessible via leur site Web des Relations Investisseurs. Une rediffusion sera également disponible pour ceux qui ne peuvent pas assister à la présentation en direct.
Elevation Oncology (Nasdaq: ELEV) hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. Joseph J. Ferra, Präsident und CEO, wird am Dienstag, den 3. Dezember 2024, um 8:30 Uhr ET an einem informellen Gespräch teilnehmen. Das Unternehmen, das sich auf die Entwicklung selektiver Krebstherapien für Patienten mit soliden Tumoren spezialisiert hat, wird eine Live-Übertragung der Veranstaltung anbieten, die über ihre Website für Investoren zugänglich ist. Eine Aufzeichnung wird ebenfalls verfügbar sein für diejenigen, die an der Live-Präsentation nicht teilnehmen können.
- None.
- None.
A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class, Claudin 18.2 ADC and is currently being evaluated in the dose expansion portion of a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic gastric/gastroesophageal adenocarcinoma that express Claudin 18.2. Additionally, we expect to nominate a development candidate for our second program, a HER3-targeting ADC for the treatment of patients with solid tumors that overexpress HER3, in 2024. For more information, visit www.ElevationOncology.com.
Elevation Oncology Investor and Media Contact
Gracie Tong
Senior Director, Investor Relations and Corporate Communications
gtong@elevationoncology.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-302314303.html
SOURCE Elevation Oncology
FAQ
When is Elevation Oncology (ELEV) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Elevation Oncology's (ELEV) presentation at the Piper Sandler Conference?
What type of presentation will Elevation Oncology (ELEV) give at the Piper Sandler Conference?
Which Elevation Oncology (ELEV) executive is presenting at the Piper Sandler Healthcare Conference?
